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Abstract
Mitochondrial metabolism and the generation of reactive oxygen
species (ROS) contribute to the acquisition of DNA mutations and
genomic instability in cancer. How genomic instability influences
the metabolic capacity of cancer cells is nevertheless poorly under-
stood. Here, we show that homologous recombination-defective
(HRD) cancers rely on oxidative metabolism to supply NAD+ and
ATP for poly(ADP-ribose) polymerase (PARP)-dependent DNA repair
mechanisms. Studies in breast and ovarian cancer HRD models
depict a metabolic shift that includes enhanced expression of the
oxidative phosphorylation (OXPHOS) pathway and its key compo-
nents and a decline in the glycolytic Warburg phenotype. Hence,
HRD cells are more sensitive to metformin and NAD+ concentration
changes. On the other hand, shifting from an OXPHOS to a highly
glycolytic metabolism interferes with the sensitivity to PARP inhi-
bitors (PARPi) in these HRD cells. This feature is associated with a
weak response to PARP inhibition in patient-derived xenografts,
emerging as a new mechanism to determine PARPi sensitivity. This
study shows a mechanistic link between two major cancer hall-
marks, which in turn suggests novel possibilities for specifically
treating HRD cancers with OXPHOS inhibitors.
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Introduction
Genomic instability and deregulation of cellular energetics are two of
the hallmarks of cancer cells, as re-defined by Hanahan and Weinberg
(2011). Genomic instability arises when mechanisms that protect
genomes from alterations in DNA are overcome. Consequently, as
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mutation rates increase, cells can adapt better to changes in the tumor
environment, response to therapies, etc. An increase in genomic insta-
bility could be caused by alterations in the DNA damage response
(DDR), including the mechanisms responsible for (i) detecting DNA
damage, (ii) DNA repair, and/or (iii) detoxification (Jackson & Bartek,
2009). The DNA repair machinery corrects, among other things,
double- and single-strand DNA breaks (DSBs and SSBs, respectively).
DSBs are repaired by processes such as homologous recombination
(HR) and non-homologous end joining (NHEJ), and SSBs are repaired
by base excision repair (BER) and nucleotide excision repair (NER)
mechanisms. BRCA1 and BRCA2 proteins play a key role in HR, and
mutations in these genes cause defective HR and increased genomic
instability (Roy et al, 2011). Poly(ADP-ribose) polymerase (PARP)
proteins are DNA damage sensors because they can bind to breaks
and nicks in DNA and transduce signals to the DNA repair machinery
by attaching branched poly(ADP-ribose) (PAR) chains to various
proteins (Krishnakumar & Kraus, 2010; Gupte et al, 2017; Lord &
Ashworth, 2017). Cancer cells with defective HR depend on alterna-
tive DNA repair pathways, such as BER and NHEJ, both of which are
promoted by PARP enzymes. This is the basis of the clinical utility of
PARP inhibitors in HR-deficient cases (Lord & Ashworth, 2017).
Tumoral cells must maintain a constant supply of nutrients and
energy to sustain the growth and cell division that characterize
cancer (Boroughs & DeBerardinis, 2015). In order to do so, a large
proportion of tumoral cells switch their metabolism to aerobic
glycolysis (the Warburg effect), a preference for increased glycolysis
regardless of the presence of oxygen (Hsu & Sabatini, 2008; Vander
Heiden et al, 2009; Ward & Thompson, 2012). Thus, glycolytic inter-
mediates expand to cope with biosynthetic pathways, such as those
involved in the synthesis of nucleotides and amino acids (Hsu &
Sabatini, 2008; Vander Heiden et al, 2009; Ward & Thompson,
2012; Hay, 2016). However, a preference for aerobic glycolysis does
not always involve reduced respiratory capacity. In fact, tumoral
cells depend on a continuing supply of TCA cycle intermediates,
such as those serving as direct precursors of lipids, and those
providing carbons and cofactors in the nucleotide and amino acid
synthesis pathways (Vyas et al, 2016). Thus, depending on the
tumoral cells’ intrinsic capacity (oncogene profile, metabolic
program, proliferative state, etc), the characteristics of the tumor
environment (e.g., with or without hypoxia, and metabolic
substrates produced by the tumoral stroma), and the effects of the
cancer treatment (e.g., presence of drugs and ROS generated by the
treatment), the metabolism of cancer cells can change and readapt.
Examples of this are cancer cells subjected to chronically low
in vitro glucose levels, which increase oxidative phosphorylation
(OXPHOS) to maintain growth (Birsoy et al, 2014), chemotherapy-
resistant breast tumoral cells, which have a higher mitochondrial
oxidative metabolic rate than do sensitive cells (Janzer et al, 2014),
and antiangiogenic treatment in breast and lung cancer models that
induce a shift from a largely glycolytic metabolism to a more oxida-
tive one (Navarro et al, 2016).
The capacity to detect and repair DNA damage and the metabolic
characteristics of a cell are coordinated (Berkers et al, 2013; Imai &
Guarente, 2014; Shimizu et al, 2014). Different repair mechanisms
rely on specific metabolites, which may, in turn, limit the capacity
of cancer cells to cope with different chemotherapies. PARP
enzymes directly depend on the cellular metabolic state, particularly
on NAD+ levels, for their functions (Krishnakumar & Kraus, 2010;
Gupte et al, 2017); hence, a direct role for PARP proteins linking
DNA damage and metabolic capacities in different situations has
been proposed (Bai et al, 2007; Sakamaki et al, 2009; Brace et al,
2016). Acute DNA damage inhibits glutamine metabolism to control
cell cycle arrest through SIRT4, a family of proteins that also depend
on NAD+ for their activity (Jeong et al, 2013). Meanwhile, DDR
upregulates the pentose phosphate pathway and glycolysis to
promote nucleotide synthesis and an open global chromatin struc-
ture (Cosentino et al, 2011; Liu et al, 2015; Efimova et al, 2016).
However, the metabolic requirements of BRCA-dependent HR DNA
repair mechanisms remain unknown. In this study, analyses of
cancer cell models, patient-derived xenografts (PDXs), and human
cancer samples reveal novel mechanisms linking HR defects to
increased oxidative metabolism. Triggering oxidative metabolism in
HR-defective (HRD) cancer cells emerges as a fundamental charac-
teristic of cancer survival due to its contribution to DNA damage
repair, a feature set that highlights additional cancer vulnerabilities,
as it emerges as a novel player in determining sensitivity to PARP
inhibitors.
Results
HR deficiency is linked to enhanced OXPHOS gene expression in
breast and ovarian cancer
To identify metabolic pathways that may be associated with
genomic instability due to HR deficiency, we integrated somatic
mutational profiles and gene expression data from the breast and
ovarian cancer studies of TCGA (Cancer Genome Atlas Research
Network, 2011; Cancer Genome Atlas Network, 2012). Tumors were
classified according to the presence (S3+) or absence (S3) of muta-
tional signature 3, originally shown to be characteristic of cases with
HR defects and BRCA1/2 mutations (Alexandrov et al, 2013). Next,
an association with changes in gene expression of metabolic path-
ways sets was analyzed using the Gene Set Enrichment Analysis
tool (Subramanian et al, 2005) and pathway annotations from the
Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al,
2017). These analyses revealed that OXPHOS and four additional
mitochondria-related metabolic sets (Table EV1) are positively asso-
ciated with the presence of the S3 signature (S3+), that is, with HR
defects in breast tumors (gene set expression analysis [GSEA] nomi-
nal P = 0.019, Fig 1A, top panel). Moreover, we also complied
BRCA1/2 mutation status of TCGA breast cancer datasets from dif-
ferent sources (cBioPortal and TCGA accessible data) (Kraya et al,
2019; Yost et al, 2019) and further analyzed the association with the
KEGG oxidative phosphorylation pathway. In multivariate regres-
sion analyses including age at diagnosis and tumor stage, overex-
pression of this pathway was also detected significantly associated
with BRCA1/2 mutations (P = 0.013, Fig 1A, middle panel). Consis-
tent with this observation, the single-sample GSEA (ssGSEA) scores
of the KEGG OXPHOS gene set were found to be negatively corre-
lated (Pearson’s correlation coefficients [PCCs] ≤ 0.15, P < 0.001)
with both BRCA1 and BRCA2 expression levels (Fig 1A, bottom
panels). Subsequently, a similar metabolic association was observed
with high-grade serous ovarian tumors positive for the mutational
signature 3: higher OXPHOS gene expression in S3+, HR-defective
tumors (false-discovery rate [FDR]-adjusted P = 0.025, Fig 1B, top
2 of 23 EMBO Molecular Medicine e11217 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Álvaro Lahiguera et al
panel) and with BRCA1/2 mutation status of TCGA ovarian cancer
datasets (P < 0.001, Fig 1B, middle panel). The OXPHOS gene set
was also found to be negatively correlated (PCCs ≤ 0.18, P < 0.01)
with BRCA1 and BRCA2 expression (Fig 1B, bottom panels).
Homologous recombination-defective tumors present a better
response (are more sensitive) to some chemotherapy treatments,
such as cisplatin in ovarian cancers (Rigakos & Razis, 2012; Safra
et al, 2014). To evaluate the link between OXPHOS metabolic activ-
ity and response to chemotherapy in HRD cancers, data from the
Cambridge Translational Cancer Research Ovarian Study 01
(https://www.ncbi.nlm.nih.gov/pubmed/18068629) were analyzed.
The level of expression of the OXPHOS gene signature was signifi-
cantly higher in pre-treated ovarian tumors that subsequently
showed higher sensitivity to carboplatin (Fig 1C, top panel). Impor-
tantly, analogous differences were found for an HRD signature
(Fig 1C, bottom panel; https://www.nature.com/articles/ncomm
s4361). Indeed, an association between the OXPHOS gene signature
in ovarian tumors and clinical outcome was evident from higher
survival probability observed in patients displaying high OXPHOS
expression (Appendix Fig S1A).
Next, to better delineate the association in ovarian cancer, we
analyzed a retrospective series of high-grade serous epithelial ovar-
ian carcinomas without or with mutations in BRCA2. Immunohisto-
chemical analyses revealed downregulation of the monocarboxylate
transporter MCT4 (which is responsible for lactate extrusion in
glycolytic cells; Fig 1D), and overexpression of the OXPHOS
complex I respiratory chain NDUFV2 subunit (one of the genes that
were increased in the HR-defective-associated S3+ signature; Fig 1E)
in BRCA2-mutated tumors relative to wild-type high-grade serous
cases. The analysis of a second independent series of high-grade
serous epithelial ovarian carcinomas (with and without mutations
in BRCA2) also showed identical changes in MCT4 and NDUFV2
protein expression by Western blot (Fig 1F). We also measured the
proliferative capacity of WT or BRCA2-mutated human ovarian
high-grade serous tumors by Ki67 staining, but we did not observe
changes in tumoral cell proliferation rates associated with the HRD
phenotype (Appendix Fig S1B).
Collectively, these results from two cancer types with frequent
inactivation of HR indicate an association between this cancer hall-
mark and enhanced OXPHOS.
Enhanced oxygen consumption in genomic instable ovarian
cancer cells
To functionally corroborate the above gene/protein expression asso-
ciations, oxidative metabolism was evaluated in cancer cell models
characterized by defective HR and high or low genomic instability
using their genomic analysis, olaparib sensitivity (high sensitivity
implies high genomic instability), and phospho(Ser129) histone
H2A.X levels (marker of double-strand DNA breaks) as surrogate
indicators (Appendix Figs S2–S4). These models included (i) murine
ID8 ovarian cancer cells wild-type, Trp53-deficient (less sensitive to
olaparib), or Trp53 and Brca2-deficient (olaparib-sensitive) (Walton
et al, 2016); (ii) SKOV-3-SC (control cells infected with an empty
vector, TP53 mutant but BRCA1/2 wild-type, less sensitive to
olaparib) or their SKOV-3-BRCA2/ 1.2 counterpart (olaparib-
sensitive); (iii) SKOV-3 cells (less sensitive to olaparib) or their
cisplatin-resistant counterpart SKOV-3-R (with high genomic
instability and olaparib-sensitive); (iv) murine ovarian cancer cells
obtained from tumors generated in mice with combinations of
genetic alterations Trp53/, myc, and Akt (less sensitive to
olaparib) or Trp53/, Brca1/, myc, and Akt (olaparib-sensitive)
(Xing & Orsulic, 2006); and (v) murine Trp53-deficient MEFs (less
sensitive to olaparib) or double Trp53/Tsc2-deficient MEFs (with
higher genomic instability and more olaparib-sensitive) (Zhang et al,
2003; Sun et al, 2014). Measurements of oxygen consumption in
these cells in real time using a high-resolution oxygraph showed that
genomic instable/HRD cells consumed oxygen at higher rates
(Figs 2A and EV1). The lowest rate of consumption was found in
ID8 control cells (i.e., wild-type for both Trp53 and Brca2;
43  4.3 pmol/s), whereas higher levels were observed in Trp53-
deleted (62  4.9 pmol/s) and, subsequently, in Trp53/Brca2-
deleted ID8 cells (79  6.1 pmol/s; Fig 2A). Similarly, SKOV-3-
BRCA2/ 1.2 cells consumed more oxygen than SKOV-3 SC control
cells (78.1  7.3 and 53.0  3.2 pmol/s, respectively, Fig EV1A),
SKOV-3-R consumed more oxygen than SKOV-3 cells (58  5 and
39  4 pmol/s, respectively, Fig EV1B), murine ovarian cancer
Trp53/, Brca1/, myc, and Akt cells consumed more oxygen than
Trp53/, myc, and Akt cells (67.5  4.0 and 54.0  2.8 pmol/s,
respectively, Fig EV1C), and double Trp53/Tsc2-deleted MEFs
consumed more oxygen than Trp53-deficient MEFs (66.3  4.2 and
33.4  4.0 pmol/s, respectively, Fig EV1D), linking increased
oxygen consumption to HR defects and greater genomic instability.
In turn, cell lines characterized by a high microsatellite instability
(MSI-H) phenotype relative to MSI stable and low microsatellite
instability cancer cell lines presented a higher expression of a signa-
ture defining mitochondrial respiratory chain complex I
(Appendix Fig S5).
Enhanced OXPHOS metabolism is coupled to decreased glycolysis
The main site of oxygen consumption in the cell is the respiratory
chain of the mitochondria. Increased oxygen consumption may be
due to higher respiratory capacity and/or a more efficient flux of
substrates to the mitochondria. Analysis of mitochondrial mass with
a mitochondria specific fluorescence dye (non-potential-dependent
MitoTracker) in ID8 cell models showed small but no significant dif-
ferences (Appendix Fig S6A). Expression of VDAC, an anion channel
in the internal mitochondrial membrane, was similarly indicative of
unaffected mitochondria mass in these models (Appendix Fig S6B).
These results suggest that the higher rates of oxygen consumption
observed in the cell sets with HRD were not caused by alteration in
mitochondria turnover or biogenesis, but instead by changes in the
flux of substrates toward oxidation.
As glucose is finely regulated to either feed the OXPHOS or
lactate production, we decided to analyze glucose metabolism in
ID8 cell models. The Trp53/Brca2-deleted cells consumed signifi-
cantly less glucose (Fig EV2A) and produced less lactate (Fig 2B)
than Trp53-deleted cells. Overall, these results indicate a drop in the
glycolytic capacity of HRD cells. To confirm this, we measured the
glycolytic flux by evaluating 3H2O production from
3H-C5-Glucose at
the enolase step of glycolysis. Glycolytic flux measured in Trp53/
Brca2-deleted cells was 18% lower than in Trp53-deleted cells
(Fig 2C). A marked drop in key glycolytic enzymes (a 50% reduc-
tion in hexokinase and a 53% reduction in lactate dehydrogenase
mRNAs; Fig EV2B) and transporters (a 55% reduction in GLUT1
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protein, the main glucose transporter; Fig 2D) paralleled changes in
glycolytic flux. Moreover, in comparison with Trp53-deleted cells,
Trp53/Brca2-deleted cells revealed higher (~ 3.7-fold) TIGAR
protein expression, an inhibitor of the glycolysis (Bensaad et al,
2006; Ko et al, 2016) (Fig 2D). These results demonstrate that HR
defects reduced glycolytic flux.
Next, we set out to establish the metabolic regulatory axis in
Trp53/Brca2-deleted cells by examining key control nodes, such as
pyruvate dehydrogenase (PDH), the mitochondrial enzyme respon-
sible for converting pyruvate to acetyl-CoA, a step prior to its
complete oxidation in the tricarboxylic acid (TCA) cycle and subject
to multiple mechanisms of regulation. One of these mechanisms of
regulation involves the phosphorylation of PDH at the E1 subunit
which renders the enzyme inactive, effectively diverting the flux of
pyruvate away from the mitochondria (Fig 2F). Extracts from
Trp53/Brca2-deleted cells had 58% lower levels of phosphorylated
PDH than those of Trp53-deleted cells (Fig 2E). As phosphorylation
blocks the activity of PDH, this result indicates that the pyruvate
pools of Trp53/Brca2-deleted cells tend to be preferentially distrib-
uted into the mitochondria, and consequently, they have a greater
capacity to fully oxidize glucose into CO2 and water. Similar
changes in phosphorylated PDH were measured in murine ovarian
cancer Trp53/, Brca1/, myc, and Akt cells and in double Trp53/
Tsc2-deleted MEFs as compared to Trp53/, myc, and Akt cells and
Trp53-deleted MEFs (Fig EV2C and D). Trp53/Brca2-deleted cells
also expressed more phosphorylated (inactive) acetyl-CoA carboxy-
lase (ACC; Fig 2E), which is a node for the regulation of fatty acid
synthesis and oxidation. This observation suggested that Trp53/
Brca2-deleted cells could also oxidize more fatty acids than Trp53-
deleted cells. To address this hypothesis, cells were incubated in the
presence of different metabolic substrates, and oxygen consumption
was measured in real time. These experiments demonstrated that
glucose was the only substrate capable of increasing oxygen
consumption specifically in Trp53/Brca2-deleted cells and ruled out
enhanced consumption of fatty acids or glutamine (Fig EV2E).
Finally, targeted metabolomic enrichment analysis using C13-U-
Glucose as a substrate was used to trace TCA cycle dynamics in
Trp53/Brca2-deleted and Trp53-deleted cells (Fig 2F). M+3 and m+4
isotopologs of fumarate, aspartate (equilibrating with the oxaloac-
etate pool), and glutamate (equilibrating with the a-ketoglutarate
pool) were enriched significantly in Trp53/Brca2-deleted cells, illus-
trating increased entry, and cycling, of fully labeled pyruvate, and is
consistent with enrichment of citrate m+5 in these same cells. These
data are in agreement with the oxidative profile shown for these
cells and their enhanced oxygen respiratory rates.
Collectively, these data indicated that OXPHOS is increased in
Trp53/Brca2-deleted cells secondary to, at least, increased contribu-
tion of glucose to mitochondrial metabolism (Fig 2F).
OXPHOS metabolism sensitizes genomically instable cells
to metformin
Enhanced OXPHOS in HR-deficient cells may foresee novel vulnera-
bilities in the corresponding tumors. Indeed, Trp53/Brca2-deleted
cells were more sensitive than Trp53-deleted cells to a blockade of
respiratory complex I (NADH-ubiquinone oxidoreductase) using
metformin (half-maximal inhibitory concentration [IC50] of
5.2  0.5 and 8.2  0.7 mM, respectively; P = 0.0006, Fig 3A) (El-
Mir et al, 2000; Owen et al, 2000; Wheaton et al, 2014). To confirm
that the effect of metformin was dependent on its effect on the mito-
chondrial respiratory chain, cells were incubated with rotenone, a
more potent inhibitor of complex I. Again, Trp53/Brca2-deleted cells
were 67% more sensitive than Trp53-deleted cells to the drug (IC50
of 16.3  1.5 and 48.9  8.2 nM, respectively; P = 0.028, Fig 3B).
Trp53/Brca2-deleted were also more sensitive to inhibition of
complex V (ATP synthase) by oligomycin than Trp53-deleted cells
(IC50 of 0.53  0.10 and 1.36  0.26 nM, respectively; P = 0.028,
Fig 3B), suggesting that multiple bioenergetic components are impli-
cated in the differential sensitivity of Trp53/Brca2-deleted cells to
metformin.
To identify the reasons for the differential effect of metformin,
we studied the effect of this drug on cell proliferation and cell
death. Metformin affected cell viability disrupting the cell cycle of
Trp53-deleted cells and Trp53/Brca2-deleted cells (Fig EV3A), with
◀ Figure 1. HR defects are associated with OXPHOS gene overexpression.A, B GSEA results regarding the association between OXPHOS gene set overexpression and positivity for mutational signature 3 (associated with HR defects) in TCGA
breast cancers (A) and TCGA ovarian cancer data (B). Top panel, enrichment score, gene ranking (based on the t-statistic of the expression differences between
negative (S3) and positive (S3+) tumors), and false-discovery rate (FDR)-adjusted P values are shown. Middle panel shows similar GSEA results using as metric the
b coefficient of differential expression between BRCA1/2 wild-type and mutant tumors, including the covariates of age at diagnosis and tumor stage. Bottom
panels, scatter plots showing the correlations (Pearson’s correlation coefficients and P values) between the ssGSEA scores of the OXPHOS gene set and the BRCA1
(top) and BRCA2 (bottom) somatic gene expression values.
C GSEA results of KEGG OXPHOS (top panel) and HRD (bottom panel) signature score comparisons between carboplatin-resistant (left) and carboplatin-sensitive
(right) ovarian tumors, using pre-treatment expression data (GSE15622 data). The normalized enrichment scores (NESs) and corresponding P values are indicated.
The NES is negative because the comparison is between resistant and sensitive tumors, so negative values mean that expression is higher in the second term (i.e.,
sensitive tumors).
D Left panel, MCT4 staining of wild-type and BRCA2-mutated high-grade serous ovarian tumors. Scale bars, 100 lm. Right panel, quantification of MCT4 levels using
the multiplicative index in tumor tissue sections from wild-type (n = 10) and BRCA2-mutated (n = 8) high-grade serous tumors. Error bars indicate the SEM.
**P = 0.0055 (two-tailed unpaired Mann–Whitney U-test).
E Left panel, NDUFV2 staining of wild-type and BRCA2-mutated high-grade serous ovarian tumors. Scale bars, 100 lm. Right panel, quantification of NDUFV2 levels
using the multiplicative index in tumor tissue sections from wild-type (n = 8) and BRCA2-mutated (n = 12) high-grade serous tumors. Error bars indicate the SEM.
*P = 0.0101 (two-tailed unpaired Mann–Whitney U-test).
F Samples from wild-type (WT, n = 5) and BRCA2-mutated (n = 6) high-grade serous ovarian tumors were lysed and immunoblotted using the indicated antibodies.
Left panel: A representative blot of two independent tumors is shown. Right panel: Bars show the relative immunoreactivity of MCT4 or NDUFV2 proteins
normalized with respect to vinculin in samples from the left. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests,
*P = 0.0317.
Source data are available online for this figure.
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no increase in apoptosis (Fig EV3B); in contrast, administering
olaparib led to a substantial increase in the number of apoptotic
cells (Fig EV3B). High OXPHOS metabolism is usually associated
with an increase in ROS. We did not detect differences in mitochon-
drial ROS basal levels between Trp53/Brca2-deleted cells and
Trp53-deleted cells, although incubation with metformin caused a
higher increase in mitochondrial ROS in Trp53/Brca2-deleted cells
than in Trp53-deleted cells, as assessed by surrogate mitoSOX label-
ing (Appendix Fig S7).
Cancer cells with defective HR are completely dependent on
alternative DNA repair pathways promoted by NAD+ and ATP-
consuming PARP enzymes, and alterations in the activity of these
enzymes will affect cell viability. In fact, Trp53/Brca2-deleted cells
presented high phospho-histone H2A.X levels when treated with
metformin (Figs 3C and EV4). To determine whether oxidative
metabolism changes observed in Trp53/Brca2-deleted cells corre-
lated with PARP activity, first we measured PARP1 protein levels.
Trp53/Brca2-deleted cells presented lower PARP1 levels compared
with Trp53-deleted cells (Fig 3D). Next, the levels of poly-ADP-ribo-
sylated (PAR) proteins were measured. PARP activity in basal condi-
tions was 25% lower in Trp53/Brca2-deleted cells than in Trp53-
deleted cells (Fig 3E), in agreement with PARP1 protein levels. As
expected, incubation with olaparib completely blocked PARP activ-
ity in both cell types. Metformin significantly affected PAR levels in
both cell types, but the effect of metformin incubation on PARP
activity was stronger in Trp53/Brca2-deleted cells (63% versus 40%
reduction, Fig 3E). In aggregate, HRD cells maintain a very low level
of PARP activity in the presence of metformin, like those observed
after PARP inhibition with olaparib. These results suggested that
OXPHOS is involved in maintaining PARP activity. To confirm this,
we increased pyruvate flux to the mitochondria by incubation with
dichloroacetate (DCA), an inhibitor of PDH kinase, therefore releas-
ing the inhibition of PDH sustained by phosphorylation by this
kinase (Stacpoole et al, 2008). As expected, DCA incubation caused
an increase in oxygen consumption (16%), but more importantly,
this increase in OXPHOS was associated with an increase in PARP
activity (Fig 3F). In all, these results confirmed that OXPHOS is
involved in maintaining PARP activity, essential for cell survival
and proliferation in HRD cells, and partially explaining the dramatic
effect of metformin in these cells.
Oxidative metabolism is necessary to maintain high ATP levels
and NAD+/NADH ratio
The above results depict a biological association between enhanced
OXPHOS and defective HR cancer cells that serves to maintain a
high level of activity of PARP enzymes. However, it was unclear
how increased levels of OXPHOS were linked to PARP activity. To
investigate this matter, we analyzed the metabolic consequences of
metformin action in these cells, by first measuring the fluxes of
glucose carbon into metabolites of the TCA cycle and its branching
pathways (Fig 4A). As expected, the inhibition of complex I by
metformin was met with a marked reduction in fluxes to TCA cycle
intermediaries as shown by reduced contribution (ratio of fully
labeled and unlabeled isotopologs) of carbons from C13-U-glucose
analyzed by targeted metabolomics (Fig 4A). However, carbon flux
and metabolite pools were unsensitive to the presence of Brca2, as
metformin affected both cell lines similarly.
Next, we studied energy charge (total ATP levels) in these cells.
Trp53/Brca2-deleted cells presented high ATP levels (74% higher)
relative to what was measured in Trp53-deleted cells (Fig 4B).
However, ATP levels after 48-h incubation with metformin dropped
by 42% in Trp53/Brca2-deleted cells compared with a milder reduc-
tion of 11% in Trp53-deleted cells (Fig 4B), suggesting that OXPHOS
metabolism is consequential for maintaining high ATP levels in
HRD cells.
We subsequently analyzed the impact of altered redox equilib-
rium in HR-deficient cells. PARP enzymes depend on NAD+ to poly-
ADP ribosylate substrates (Krishnakumar & Kraus, 2010), and
consequently, HRD cells may require a permanently high NAD+/
NADH ratio that is controlled by the metabolic state of the cell. We
hypothesized that limiting accessibility to NAD+ could severely
◀ Figure 2. Genomic instable cell models show high oxygen consumption and decreased glycolytic flux.A Oxygen consumption rates measured using an Oxygraph-2K in ID8 control (n = 10), ID8 Trp53-deleted (n = 18), and double Trp53/Brca2-deleted (n = 17) mouse
ovarian tumor cells. The bars indicate the mean and standard error (SEM). Statistical significance of two-tailed unpaired Mann–Whitney U-tests: ID8 control versus
ID8 Trp53-deleted, *P = 0.0266; ID8 control versus double Trp53/Brca2-deleted, ***P = 0.0009; ID8 Trp53-deleted versus double Trp53/Brca2-deleted, *P = 0.0204.
B Lactate production (mmol) was measured in DMEM from ID8 Trp53-deleted (n = 4, 0.36, 0.42, 0.37, and 0. 38) and Trp53/Brca2-deleted (n = 4, 0.33, 0.31, 0.33, and
0.33) ovarian tumor cells grown for 24 h. Data were normalized with respect to protein content. Error bars indicate the SEM. Statistical significance of two-tailed
unpaired Mann–Whitney U-tests, *P = 0.0236.
C Glycolytic flux was measured in ID8 Trp53-deleted (n = 4, 0.346, 0.361, 0.377, and 0.400) and Trp53/Brca2-deleted (n = 3, 0.276, 0.324, and 0.314) ovarian tumor cells
grown for 24 h in DMEM complete medium and in the presence 3H-glucose for the final 60 min. Measurements (in pmol 3H H2O produced) were normalized relative
to protein content. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests, *P = 0.0153.
D ID8 Trp53-deleted (n = 4) and Trp53/Brca2-deleted (n = 4) ovarian tumor cells were grown in complete DMEM for 3 days. Cells were lysed and immunoblotted using
the indicated antibodies.
E ID8 Trp53-deleted (n = 4) and Trp53/Brca2-deleted (n = 4) ovarian tumor cells were grown in complete DMEM for 3 days. Cells were lysed and immunoblotted using
the indicated antibodies.
F Targeted metabolomic enrichment analysis using C13-U-Glucose as substrate. M+3 (left panels) isotopolog enrichment and m+4 (right panels) isotopolog enrichment
of fumarate, aspartate (equilibrating with the oxaloacetate pool), and glutamate (equilibrating with the a-ketoglutarate pool) are shown to illustrate TCA cycle entry
of pyruvate carbons, and cycling. Citrate m+5 enrichment is also shown as a measure of the capacity of the mitochondria to oxidize fully labeled pyruvate. The mean
of four replicates for each cell line is shown. Error bars indicate the SEM. Statistical significance of citrate m+5 by two-tailed unpaired Mann–Whitney U-test, Trp53-
deleted versus Trp53/Brca2-deleted cells *P = 0.0286. Statistical significance of one-way ANOVA, Holm–Sidak’s multiple comparisons test Trp53-deleted versus Trp53/
Brca2-deleted cells: Glutamate, m+3 ***P < 0.0001, m+4 ***P < 0.0001; fumarate, m+3 *P = 0.0033, m+4 *P = 0.0051; aspartate, m+3 ***P < 0.0001, m+4
***P < 0.0001.
Source data are available online for this figure.
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affect the survival capacity of HRD cells. To test this, the NAD+/
NADH ratio was measured in the cell models after 48 h in the pres-
ence or absence of metformin. Relative to Trp53-deleted cells,
Trp53/Brca2-deleted cells showed a 14% greater NAD+/NADH
ratio, mainly due to 46% higher NAD+ levels (Figs 4C and EV5A).
Metformin incubation reduced the ratio only in Trp53/Brca2-deleted
cells (48%, Fig 4C), a drop caused by a decrease in NAD+ and an
increase in NADH (Fig EV5A and B).
These results suggest that reduced ATP and NAD+ levels can
substantially impair the survival of defective HR cancer cells. To
evaluate this hypothesis, we examined the effect of metformin
under a range of cell culture conditions. Restriction of carbon
sources by incubation with DMEM in the absence of pyruvate
increased the sensitivity to metformin in all cancer cell lines tested
(Fig 4D), as previously described (Gui et al, 2016; Hodeib et al,
2018). In fact, differences in metformin’s IC50 between Trp53/Brca2-
deleted and Trp53-deleted cells disappeared in the absence of pyru-
vate. However, adding pyruvate to the medium, which raised
NAD+ (Gui et al, 2016), conferred greater resistance to metformin
in both Trp53-deleted and Trp53/Brca2-deleted cells (Fig 4D) and
correlated with higher levels of PAR proteins (Fig 4E). Effects of
pyruvate on metformin sensitivity were consistent with changes in
ATP levels (Fig EV5C) and in NAD+/NADH ratio (Fig 4F) associ-
ated with pyruvate and/or metformin addition.
The use of NAD+ by poly-ADP-ribosylating enzymes reduces
NAD+ levels and releases nicotinamide (NAM). NAD+ levels could
be restored by de novo synthesis (from tryptophan in de novo
synthesis pathway) or by salvage pathways from NAM or nicotinic
acid (NA) (Canto et al, 2015). In addition, changes in cell metabo-
lism also modify available levels of NAD+. To determine the impor-
tance of each pathway in the differential response to metformin, we
assessed the effect of tryptophan and inhibitors of the enzymes
involved in the salvage pathways required for restoring NAD+
levels: GMX1777 (an inhibitor of NAMPT, the key enzyme of NAM
utilization) and 2-hydroxypyridine-3-carboxylic acid (an inhibitor of
NAPRT, the key enzyme of NA utilization). Only GMX1777 reduced
survival directly in both subsets of ID8 cell (Trp53/Brca2-deleted
and Trp53-deleted) with similar sensitivity (IC50 values of 33 nM
and 30 nM, respectively). However, when co-administered with
metformin, GMX1777 had a differential effect on Trp53/Brca2-
deleted cells, reducing metformin IC50 by 63% compared with a
19% reduction in Trp53-deleted cells (Fig 4G). Conversely, when
we treated Trp53/Brca2-deleted cells with 2 mM nicotinamide,
metformin IC50 increased (Fig 4H). Finally, analysis of differential
cancer cell responses to the NMPRT inhibitor FK866 revealed signifi-
cantly higher sensibility in cell lines characterized by a high
microsatellite instability (MSI-H) phenotype relative to MSI stable
and low (Fig 4I). Taken together, these results confirmed that
OXPHOS regulates NAD+ levels and the NAD+/NADH ratio, and
that these are key elements of the metformin site of action.
Metformin blocks growth of HR-defective tumors in vivo
This inhibitory capacity of metformin in defective HR cells in culture
prompted us to evaluate this inhibitor in the context of ovarian
cancer growth in vivo. To this end, we first generated palpable
tumors from ID8 Trp53-deleted or Trp53/Brca2-deleted cells injected
into the ovary of C57/BL-6 mice. Tumor-bearing mice were then
randomized into two groups for one additional month and treated
with saline or metformin. Metformin treatment significantly reduced
tumor growth (0.12 cm3 versus 0.24 cm3 tumor volume, in treated
and control groups, respectively) only in the ID8 Trp53/Brca2-
deleted cells (Fig 5A and B), as compared to ID8 Trp53-deleted cells
that were unaffected by metformin treatment (0.13 cm3 versus
0.11 cm3 tumor volume, in control and metformin-treated groups,
respectively).
Finally, we evaluated the effects of metformin on orthotopic pre-
clinical models of post-surgery tumor samples from one high-grade
◀ Figure 3. HRD cells are more sensitive to metformin.A ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of metformin concentrations. Cell viability was measured as
the frequency of cells revealed by violet crystal staining. Results are expressed relative to the control in the absence of metformin. Each data point represents the
mean and SEM of eight independent determinations.
B ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of metformin (Met), rotenone (Rot), or oligomycin (Oligom)
concentrations. Cell viability was measured as the frequency of cells revealed by violet crystal staining. The IC50 was determined relative to ID8 Trp53-deleted cells.
Each data point represents the mean and SEM of n = 16 (Met), n = 14 (Rote), or n = 4 (Oligom) independent determinations. Statistical significance of two-tailed
unpaired Mann–Whitney U-tests: Trp53-deleted versus Trp53/Brca2-deleted in the metformin treatment ***P = 0.0006; Trp53-deleted versus Trp53/Brca2-deleted in
the rotenone treatment ****P = 0.0001; Trp53-deleted versus Trp53/Brca2-deleted in the oligomycin treatment *P = 0.028.
C Phospho-histone H2A.X and tubulin expression were measured by immunoblotting in ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells incubated for
48 h with complete DMEM in the absence (C) or presence of 5 mM metformin (Met), or for the last 12 h in the presence of 5 lM olaparib (O). A representative blot of
three independent experiments is shown.
D ID8 Trp53-deleted (n = 4) and Trp53/Brca2-deleted (n = 4) ovarian tumor cells grown in complete medium were lysed and immunoblotted using the indicated
antibodies. A representative blot of three independent experiments is shown.
E Top panel: Poly-ADP-ribosylated (PAR) proteins and tubulin (as a loading control) expression were measured by immunoblotting in ID8 Trp53-deleted and Trp53/
Brca2-deleted ovarian tumor cells incubated for 12 h with complete DMEM in the absence (C) or presence of 5 lM olaparib (O) or 5 mM metformin (Met). A
representative blot of four independent experiments is shown. Bottom panel: Bars show the relative immunoreactivity of PAR normalized with respect to tubulin in
samples from the top. The mean of five independent experiments is shown. Error bars indicate the SEM. Statistical significance of one-way ANOVA, Tukey’s multiple
comparisons test: *P < 0.05; **P < 0.01; ***P < 0.005.
F Top panel: Poly-ADP-ribosylated (PAR) proteins and tubulin (as a loading control) expression were measured by immunoblotting in ID8 Trp53/Brca2-deleted ovarian
tumor cells incubated for 48 h with complete DMEM in the absence (C) or presence of 10 mM dichloroacetate (DCA). A representative blot of five independent
experiments is shown. Bottom panel: Bars show the relative immunoreactivity of PAR normalized with respect to tubulin in samples from the top. The mean of five
independent experiments is shown. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests: *P = 0.0159.
Source data are available online for this figure.
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serous ovarian tumor WT for BRCA genes (OVA260 tumor), and
one high-grade serous ovarian tumor with a deletion of the exon
20 c.(5243_5277+2788del; 5277+2916_5277+2946delinsGG) of the
BRCA1 gene, implanted in nude mice. Mice bearing these tumors
were randomized after implantation into two groups, and when a
palpable intra-abdominal mass was detected (3 months), animals
were treated with saline or metformin for one additional month.
Again, in these PDX models metformin treatment only significantly
reduced tumor growth in the BRCA1 mutated model (Fig 5C and D),
with a tumor volume after treatment of 0.37 cm3 in control versus
0.19 cm3 in metformin-treated animals, whereas WT BRCAs tumors
had a volume post-treatment of 0.66 cm3 versus 0.56 mm3 in
control and metformin-treated mice, respectively.
In all, these results confirmed that the effect of metformin on
defective HR tumors was also observed in vivo and could have
consequential implications for the treatment of this kind of cancers.
Blocking OXPHOS and increasing glycolysis limit the effect of
PARP inhibitors
Having established that HRD cells are more sensitive to OXPHOS
inhibition, we examined the effect of combining OXPHOS inhibi-
tors with PARP activity inhibitors, such as olaparib. Surprisingly,
incubation of Trp53/Brca2-deleted ID8 cells with metformin not
only had no synergistic activity when combined with olaparib,
but it was in fact antagonistic; metformin incubation increased
the IC50 of olaparib in a dose-dependent manner (Fig 6A), from
0.72 lM in the absence of metformin, to 2.67 and 4.71 lM with
2 and 5 mM metformin, respectively. These results were also
observed in Trp53-deleted cells (3.29, 3.91, and 5.78 lM, respec-
tively, Fig 6A), leading to equivalent olaparib sensitivity in
Trp53/Brca2-deleted and Trp53-deleted ID8 cells in the presence
of 5 mM metformin.
To clarify whether resistance to olaparib was related to the meta-
bolic implications of metformin, we used rotenone, another inhi-
bitor of the respiratory chain. Our results indicated that rotenone
also increased the IC50 for olaparib (Fig 6B), although it was less
effective than metformin. We then examined the effect of metformin
on the capacity of olaparib to block PARP activity in Trp53/Brca2-
deleted cells. As illustrated in Fig 6C, metformin partially blocked
the impact of olaparib on the levels of PAR proteins. One of the key
effects of PARP inhibitors is to trap PARP proteins at zones with
DNA damage (Murai et al, 2012). To determine whether metformin
could affect this mechanism of action of PARP inhibitors, we evalu-
ated the presence of PARP1 protein in chromatin in the presence or
absence of olaparib, or in combination with metformin. Metformin
decreased trapping of PARP1 to DNA induced by olaparib (line 3 in
the different conditions, Fig 6D).
◀ Figure 4. Metformin affects metabolites of the TCA cycle, ATP, and the NAD+/NADH ratio.A Fluxes of glucose carbon into metabolites of the TCA cycle and its branching pathways. The ratio of fully labeled and unlabeled isotopolog amount is shown for each
metabolite as analyzed by targeted metabolomics. The mean of four replicates for each cell line is shown. Error bars indicate the SEM. Statistical significance of one-
way ANOVA: ***P < 0.001.
B ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 48 h with complete DMEM in the absence or presence of 5 mM metformin. Cells
were then lysed, and total ATP levels are measured as indicated. Data were normalized with respect to protein content. The mean of seven independent experiments
is shown. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests: ID8 Trp53-deleted versus double Trp53/Brca2-deleted,
***P = 0.0006; ID8 double Trp53/Brca2-deleted control versus metformin, ***P = 0.0006.
C ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 48 h with complete DMEM in the absence or presence of 5 mM metformin. Cells
were then lysed and total NAD+ and total NADH levels measured as indicated. Data were normalized with respect to protein content. Ratios between NAD+ and
NADH levels in each situation were calculated. The mean of three (ID8 Trp53-deleted, 1.45, 1.97, and 1.13 in the absence and 1.63, 0.96, and 1.29 in the presence of
metformin) and four independent experiments (ID8 Trp53/Brca2-deleted 1.93, 1.84, 2.17, and 1.40 in the absence and 1.06, 1.10, 0.99, and 1.06 in the presence of
metformin) is shown. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests: ID8 double Trp53/Brca2-deleted control
versus metformin, *P = 0.0286.
D ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of metformin concentrations in complete DMEM without
pyruvate and complete DMEM and 1 mM pyruvate (+Pyr). Cell viability was measured as the frequency of cells stained with crystal violet. The IC50 was determined
by representing results relative to the control without metformin. Bars represent the mean and SEM of six independent determinations. Statistical significance of
one-way ANOVA, Tukey’s multiple comparisons test, **P < 0.01.
E ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 48 h with complete DMEM without pyruvate or complete DMEM and 1 mM
pyruvate in the absence or presence of 5 mM metformin. Cells were lysed and immunoblotted using the indicated antibodies. A representative blot of three
independent experiments is shown.
F ID8 Trp53-deleted (n = 3) and Trp53/Brca2-deleted (n = 3) ovarian tumor cells were incubated for 2 days in normal DMEM in the absence or presence of 5 mM
metformin and in the absence or presence of 1 mM pyruvate. Cells were then lysed and total NAD+ and total NADH levels measured as indicated. Data were
normalized with respect to protein content. Ratios between NAD+ and NADH levels in each situation were calculated. Error bars indicate the SEM. Statistical
significance of one-way ANOVA, Tukey’s multiple comparisons test, *P < 0.05.
G ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of metformin concentrations in complete DMEM, or in
complete DMEM and the indicated concentrations of GMX1777 (nM). Cell viability was measured as the frequency of cells revealed by crystal violet staining. The IC50
was determined by representing results relative to a zero level of inhibitor. Bars represent the mean and SEM of four independent determinations. Statistical
significance of two-tailed unpaired Mann–Whitney U-tests: ***P = 0.0006.
H ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of metformin concentrations in complete medium without
pyruvate, or in complete medium and 1 mM nicotinamide (+Nico). Cell viability was measured as the frequency of cells stained with crystal violet. The IC50 was
determined by representing results relative to the control. Bars represent the mean and SEM of six independent determinations. Statistical significance of two-tailed
unpaired Mann–Whitney U-tests, *P = 0.028.
I Box plot showing higher sensibility (i.e., lower standardized half-maximal inhibitory concentration [IC50]) to the NMPRT inhibitor FK866 in cancer cell lines classified
as MSI-H (high genomic instability, n = 60) relative to MSI stable (MSS) or MSI-low (MSI-L; low genomic instability, n = 926). The box plots show a typical display
consisting of a median value depicted by the line in the center of the box; an interquartile range (IQR; 25th to the 75th percentile) depicted by the box; the maximum
(Q3 + 1.5*IQR) and minimum (Q1  1.5*IQR) values depicted by the whisker; and outliers shown as individual circles. The P value of the t-test is shown.
Source data are available online for this figure.
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To study which metabolic changes induced by metformin affect
olaparib sensitivity, once again, we changed cell culture conditions.
Increased olaparib IC50 by metformin was mimicked by pyruvate
alone, an effect that was more evident in Trp53/Brca2-deleted cells
(Fig 7A). This confirmed that olaparib resistance was mediated by
metabolic perturbations. Metformin in the presence of pyruvate
showed the greatest increase in olaparib IC50, reaching an equiva-
lent sensitivity to Trp53-deleted cells. These results suggested that
PARP inhibitors require active OXPHOS metabolism to influence cell
viability. To test this hypothesis, we first measured oxygen
consumption in cells incubated for 2 days under the same condi-
tions in which we had analyzed olaparib sensitivity. Metformin
more than halved the oxygen consumption rate in all cells and
under all conditions analyzed (Fig 7B). In contrast, metformin
increased glycolysis in Trp53-deleted cells independently of pyru-
vate, although this increase only occurred in Trp53/Brca2-deleted
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Figure 5. Metformin blocks growth of HR-defective tumors in vivo.
A, B ID8 Trp53-deleted (A) and Trp53/Brca2-deleted (B) ovarian tumor cells were injected in the ovary of C57/BL-6 mice. After 1 month, animals were treated with
vehicle or metformin (100 mg/kg) for 4 weeks. Results are the mean and SEM of 8 controls and 8 metformin-treated animals (A) or of eight controls and 12
metformin-treated animals (B). Statistical significance of two-tailed unpaired Mann–Whitney U-tests: *P = 0.0446.
C Nude mice with orthotopically implanted BRCA1 WT OVA260 ovarian tumors were treated with vehicle or metformin (100 mg/kg) for 4 weeks. Results are the
mean and SEM of five control tumors and five metformin-treated tumors. Statistical significance of two-tailed unpaired Mann–Whitney U-test: P = 0.8016.
D Mice with orthotopically implanted BRCA1-mutated OVA265 ovarian tumors were treated with vehicle or metformin (100 mg/kg) for 4 weeks. Results are the mean
and SEM of seven control tumors and seven metformin-treated tumors. Statistical significance of two-tailed unpaired Mann–Whitney U-tests: *P = 0.0105.
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cells in the presence of pyruvate (Fig 7C). The combination of
metformin with pyruvate yielded similar levels of glycolytic flux in
Trp53/Brca2-deleted and in Trp53-deleted cells (Fig 7C). These
results suggested that a shift to a more glycolytic metabolism was
responsible for olaparib resistance. To confirm this, we decreased
glycolysis by incubation with dichloroacetate (DCA). Addition of
DCA to Trp53-deleted and Trp53/Brca2-deleted cells was sufficient
to increase sensitivity to olaparib (Fig 7D).
Tumors that have a glycolytic metabolic profile have a weaker
response to olaparib
Our results suggested an alternative mechanism for resistance to
olaparib inhibitors in tumors in which OXPHOS is reduced and the
glycolytic metabolism in cancer cells is increased. To investigate this
possibility, we analyzed expression data from PDX breast cancer
models originating from BRCA1 mutation carriers whose sensitivity
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to olaparib had also been characterized ((Cruz et al, 2018) and
Appendix Fig S8). In the collection of BRCA1-mutant PDXs, a higher
level of expression of OXPHOS gene sets and the respiratory chain
complex I gene set was detected in the olaparib-sensitive models
than in the olaparib-resistant PDX models (Fig 7E). To validate
these findings, the levels of expression of the monocarboxylate
transporter MCT4 were analyzed by immunohistochemistry. MCT4
expression was lower in these tumors compared with the olaparib-
resistant PDXs (Fig 7F). These results confirmed that increased
glycolytic metabolism is an alternative mechanism of resistance to
PARP inhibition and, therefore, that efficacy of olaparib may be
conditioned by the metabolic profile of the cell.
Discussion
This study demonstrates that cancer cells with HR deficiency
undergo a shift from a classical Warburg glycolytic phenotype to
one exhibiting increased oxidative metabolism. Normal untrans-
formed cells exposed to acute or chronic DNA damage show
increased OXPHOS due to the stimulation of mitochondrial fatty
acid oxidation (Brace et al, 2016). Given this, it is not surprising
that cells that are constantly subjected to genomic instability and
problems in the repair systems have adapted their metabolism by
increasing oxygen consumption. However, the dependence of HRD
cancer cells revealed here highlights a novel cancer vulnerability
and provides a complementary explanation of the differential PARP
inhibitor responses. Moreover, our results provide a mechanistic
explanation, and expand upon previous observations, of the
increase in the abundance of TCA intermediates in BRCA1- and
p53-deficient cancer models (Breitkopf et al, 2017) and of the
higher mitochondrial metabolic rate observed in MCF10A BRCA1
haplo-insufficient cells (Cuyas et al, 2016). In the context of HR
deficiency, OXPHOS activity proves to be fundamental for maintain-
ing the ATP and NAD+ levels required for the alternative DNA
repair mechanisms that ensure cancer survival. The depicted mech-
anism may also play a role in the emergence of resistance to vari-
ous DNA-damaging drugs or treatments. Indeed, some oncogenes
redirect their metabolism to increase mitochondrial oxidation in
order to boost the capacity to detoxify ROS caused by different
drugs (e.g., MITF in melanomas) (Vazquez et al, 2013), and recent
studies have shown increases in OXPHOS metabolism to be associ-
ated with resistance to different drugs in various cancer types (Bosc
et al, 2017; Farge et al, 2017; Lee et al, 2017). This increase in
OXPHOS in HRD cancer cells is caused by a greater capacity to
oxidize metabolites, especially glucose through increased PDH
activity, without apparent changes in the total mitochondrial mass.
In the case of oncogenic transformation, OXPHOS metabolism
increases due to the rise in mitochondrial biogenesis that stems
from the greater activity of transcription factors such as PGC1a
(Vazquez et al, 2013) and MYC (Lee et al, 2017). Although we did
not detect significant changes in PGC1a levels or in mitochondrial
mass in any of our models, we cannot rule out the possibility that,
in other cancer settings, genomic instability might promote mito-
chondrial biogenesis.
Why is this increase in OXPHOS metabolism necessary in HRD
tumoral cells? Our results suggest that the shift in the metabolic
capacity of cells is directed toward maintaining high levels of ATP
and NAD+, for the purpose of ensuring PARP-dependent DNA
repair activity and thereby cell survival. Cancer cells have a very
low NAD+/NADH ratio, and changes in this ratio are more closely
associated with tumor growth than is the ATP/ADP ratio (Vander
Heiden & DeBerardinis, 2017). In fact, between one-third and 80%
of the NAD+ is consumed by PARP enzymes in cells exposed to
DNA damage, and the extent of this NAD+ consumption is greater
in cells with DNA repair dysfunction than in normally repairing cells
(Liu et al, 2018). Moreover, normal cells undergo a reduction in
NAD+ levels and an increase in oxidative phosphorylation when
exposed to DNA damage (Brace et al, 2016). If NAD+ levels are
reduced, for example, by limiting the carbon sources (glucose or
pyruvate) or by inhibiting NAD+ synthesis/recycling, then cancer
cells become more sensitive to other stresses, such as cytotoxic
agents and PARP inhibitors (Bajrami et al, 2012; Chan et al, 2014;
Piacente et al, 2017), or to the blockage of OXPHOS (our results, see
later). Conversely, if the NAD+/NADH ratio rises, for example, by
incubation with pyruvate or the addition of an exogenous source of
NAD+, cells become more resistant to stresses ((Gui et al, 2016;
Hodeib et al, 2018) and our results). This effect and a drop in ATP
levels are much more important in cells that depend entirely on
PARP to repair DNA damage, as our results show.
◀ Figure 6. Metformin reduces olaparib sensitivity.A ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of olaparib concentrations in the absence (0 Met) or presence
of 2 mM or 5 mM metformin. Cell viability was measured as the frequency of cells stained with crystal violet. The IC50 was determined by representing results
relative to the control. Each data point represents the mean and SEM of five independent determinations. Statistical significance of one-way ANOVA (P < 0.0001) and
two-tailed unpaired Mann–Whitney U-tests: ID8 Trp53-deleted in the absence of metformin compared with 5 mM metformin *P = 0.0176; ID8 Trp53-deleted and
Trp53/Brca2-deleted in the absence of metformin ***P = 0.0003; ID8 Trp53/Brca2-deleted in the absence of metformin compared with 2 mM metformin
(**P = 0.0023) or with 5 mM metformin (***P = 0.0003).
B ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days over a range of olaparib concentrations in the absence or presence of 5 nM
rotenone. Cell viability was measured by counting the number of cells stained with crystal violet. The IC50 was determined by representing results relative to the
control. Each data point represents the mean and SEM of four independent determinations. Statistical significance of two-tailed unpaired Mann–Whitney U-tests:
*P = 0.0286.
C ID8 Trp53/Brca2-deleted ovarian tumor cells were incubated for 48 h with complete DMEM in the presence of 0.7, 1.5, or 3 lM olaparib and the presence or absence
of 5 mM metformin. Cells were lysed and immunoblotted using the indicated antibodies. Top panel: A representative blot of four independent experiments is shown.
Bottom panel: Bars show the relative immunoreactivity of PAR normalized with respect to tubulin in samples from the top panel (3 lM olaparib). The mean of seven
independent experiments is shown. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests: *P = 0.0169.
D ID8 Trp53/Brca2-deleted ovarian tumor cells were incubated for 24 h with complete DMEM in the presence or absence of 5 lM olaparib and the presence or absence
of 5 mM metformin. Cells were lysed and various nuclear fractions obtained as described. Samples were immunoblotted using the indicated antibodies. A
representative blot of three independent experiments is shown.
Source data are available online for this figure.
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Our work also highlights the importance of OXPHOS inhibitors,
such as metformin, in treating BRCA1/2-mutated cancers and other
types of tumors affected by HR defects. Metformin causes a combi-
nation of effects at different levels, such as ROS accumulation, alter-
ations of the redox state, and mitochondrial metabolism, all of
which are effects that depend on substrate availability (Liu et al,
2018). Our results suggest that metformin alters these pathways in
BRCA1/2-mutated cells, but those that explain the differential effect
on HRD cells are the alteration of the redox state and of the ATP
levels, leading to a drop in the capacity to repair damaged DNA. In
other cancer cells, with wild-type status of BRCA1/2, metformin
causes an increase in NADH levels, but not as much in NAD+ (Liu
et al, 2016; Hodeib et al, 2018). In our study, due to the extensive
consumption of NAD+ by PARP enzymes in HRD cells, we observed
a combined effect, a drop in NAD+ levels after short-term
metformin treatment and an increase in NADH over the long term.
The beneficial effects of biguanidines (metformin, phenformin, etc.)
in the treatment of some cancers have been evaluated epidemiologi-
cally (Evans et al, 2005; Jiralerspong et al, 2009; Libby et al, 2009;
Decensi et al, 2010) and at the molecular level (Liu et al, 2016; Bosc
et al, 2017). In fact, other OXPHOS inhibitors are being developed
to treat cancer (Bosc et al, 2017; Molina et al, 2018). Our study
depicts a mechanistic model for their clinical rationale in the context
of HR deficiency.
A second highlight of our work is that a high rate of glycolytic
metabolism decreases the effect of olaparib on tumoral cells due to
a reduction in the capacity of olaparib to block PARP activity and
poly-ADP protein ribosylation. Our results indicate that by modify-
ing the metabolic capacity, either by inhibiting complex I with
metformin or rotenone, or by adding or not adding pyruvate or
DCA, the sensitivity of cells to olaparib is modified. The molecular
mechanism involved seems to be related to alterations in the capac-
ity of olaparib to block PARP activity and trap PARP on the chro-
matin, one of the major mechanisms by which PARP inhibitors
work (Murai et al, 2012; Shen et al, 2015). Another explanation
could be that the alteration of cell cycle caused by metformin affects
olaparib’s capacity to block PARP. In fact, DNA repair protein
expression depends on progression during the cell cycle. WEE1
tyrosine kinase blocks cell cycle progression, and its inhibition
increases olaparib sensitivity (Garcia et al, 2017). Metformin, by
blocking cell cycle and impairing alternative DNA repair mecha-
nisms to HR, should cause the opposite effect, i.e., decreasing
olaparib sensitivity. Moreover, a high glycolytic rate has been
shown to protect cells from apoptosis induced by deprivation of
growth factors (Vander Heiden et al, 2001; El Mjiyad et al, 2011).
By increasing glycolysis, metformin could alter the capacity of
olaparib to induce apoptosis.
As a consequence of the poor effect of PARP inhibitors in cells
that shifted to a more glycolytic metabolism, increasing glycolysis
emerges as an alternative mechanism for reducing olaparib sensi-
tivity. Several mechanisms involved in innate or generated resis-
tance to PARP inhibitors have been described (reviewed in Ref.
(Bitler et al, 2017; Liao et al, 2018)), affecting inhibitor efflux
(Rottenberg et al, 2008), restoration of PARP function (Gogola
et al, 2018) or homologous repair mechanisms (Norquist et al,
2011; Barber et al, 2013), overstimulation of other DNA repair
mechanisms (Panier & Boulton, 2014), and alteration of DNA
replication (Ray Chaudhuri et al, 2016). Our results imply that
the metabolic profile of a tumor also determines its sensitivity to
olaparib. If a tumor presents a high rate of glycolytic metabolism
it will be relatively insensitive to olaparib, while oxidative meta-
bolism assures a strong response to the drug. Thus, analysis of
the metabolic profile of a tumor will give a good indication of
olaparib response and highlight a new way of selecting patients
in whom PARP inhibitors are less effective. Our results also indi-
cate that blocking glycolysis resensitizes tumors to olaparib,
providing the basis for possible alternatives to avoid resistance in
these situations.
◀ Figure 7. Increase in glycolytic metabolism is associated with an olaparib-resistant phenotype.A ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days in complete DMEM over a range of olaparib concentrations in the absence
or presence of 2 mM metformin, and in the absence or presence of 1 mM pyruvate. Cell viability was measured as the frequency of cells stained with crystal violet.
The IC50 was determined by representing results relative to the control. Each data point represents the mean and SEM of five independent determinations. Statistical
significance of two-tailed unpaired Mann–Whitney U-tests: Trp53/Brca2-deleted in the absence of pyruvate and metformin compared with cells in the absence of
pyruvate and the presence of metformin (*P = 0.0286), in the presence of pyruvate and the absence of metformin (*P = 0.0238), and in the presence of pyruvate and
metformin (*P = 0.0286).
B Oxygen consumption rates measured using an Oxygraph-2K in ID8 Trp53-deleted (n = 3) and Trp53/Brca2-deleted (n = 3) ovarian tumor cells. Cells were incubated
for 2 days in normal DMEM in the absence or presence of 2 mM metformin and in the absence or presence of 1 mM pyruvate. Each data point represents the mean
and SEM.
C Glycolytic flux was measured in ID8 Trp53-deleted (n = 4) and Trp53/Brca2-deleted (n = 4) ovarian tumor cells grown for 2 days in normal DMEM in the absence or
presence of 2 mM metformin and in the absence or presence of 1 mM pyruvate. Cells were incubated for 1 h in the presence of 3H glucose. Values (in pmol 3H H2O
produced) were normalized with respect to protein content. Error bars indicate the SEM. Statistical significance of two-tailed unpaired Mann–Whitney U-tests: Trp53-
deleted cells in the absence of pyruvate and metformin compared with cells in the absence of pyruvate and presence of metformin (*P = 0.0286), and in Trp53/Brca2-
deleted cells comparing cells in the presence of pyruvate and the absence of metformin and in the presence of pyruvate and metformin (*P = 0.0286).
D ID8 Trp53-deleted and Trp53/Brca2-deleted ovarian tumor cells were incubated for 3 days in normal DMEM over a range of olaparib concentrations in the absence or
presence of 10 mM dichloroacetate. Cell viability was measured as the frequency of cells stained with crystal violet. The IC50 was determined by representing results
relative to the control. Each data point represents the mean and SEM of six independent determinations. Statistical significance of two-tailed unpaired Mann–
Whitney U-tests: in ID8 Trp53-deleted (*P = 0.0303) and in Trp53/Brca2-deleted ovarian tumor cells (**P = 0.022).
E Differential signature expression (based on ssGSEA scores) of olaparib-sensitive (n = 5) and olaparib-resistant (n = 22) PDXs. The results are shown for KEGG OXPHOS,
respiratory chain complex I, and Mootha OXPHOS gene sets. The box plots show a typical display consisting of a median value depicted by the line in the center of
the box; an interquartile range (IQR; 25th to the 75th percentile) depicted by the box; and the maximum (Q3 + 1.5*IQR) and minimum (Q1  1.5*IQR) values depicted
by the whisker. Statistical significance of one-tailed unpaired Mann–Whitney U-tests is indicated.
F Left panel, MCT4 staining in BRCA1-mutated olaparib-sensitive or olaparib-resistant breast cancer PDXs. Scale bars, 100 lm. Right panel, graphs depicting differences
in MCT4 staining (multiplicative index) between PDX subgroups (olaparib-sensitive, n = 5; olaparib-resistant, n = 6). The bars indicate the mean and standard error
(SEM). Statistical significance of two-tailed unpaired Mann–Whitney U-test, **P = 0.0087.
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Materials and Methods
Chemical compounds
Olaparib was obtained from LC Laboratories (Woburn, MA) and
was diluted in DMSO. Cell culture media, FBS, glutamine, pyruvate,
and antibiotics were obtained from Gibco (Thermo Fisher Scientific,
Waltham, MA). Metformin (cat. D150959), nicotinamide (Cat.
72340), GMX1777, rotenone (Cat. R8875), dichloroacetate (Cat.
347795), and other reagents were of analytical or molecular biology
grade and were purchased from Sigma-Aldrich (St Louis, MO).
Patients
Samples and data from patients in this study were provided by the
IDIBGI Biobank (Biobanc IDIBGI, B.0000872) and from the tumor
tissue bank of the Hospital of Bellvitge-IDIBELL. They were
processed following standard operating procedures, with the appro-
priate approval of the Ethics and Scientific Committees and
conformed to the principles set out in the WMA Declaration of
Helsinki. A signed informed consent was obtained from each
patient.
ID8Trp53-deleted or Trp53/Brca2-deleted cells in vivo studies
ID8 Trp53-deleted or Trp53/Brca2-deleted cells were used to gener-
ate orthotopic ovarian tumors in 7-week-old female C57/BL-6 mice.
Mice were anesthetized with isoflurane, and 2 millions of cells were
injected into the ovary in 20 ll of DMEM. When a palpable intra-
abdominal mass was detected (1 month), animals were randomized
into two groups with similar tumor volumes and metformin
(100 mg/kg) was administered intraperitoneally every day from
Monday to Friday for 4 weeks. Control group mice received
intraperitoneal sterile serum under the same schedule as metformin-
treated mice. All mice also received a subcutaneous injection of
500 ll of 5% glucose solution. The treatments had no significant
effect on mouse body weight, and the animals appeared healthy and
active throughout the study. Tumor response was evaluated at the
moment of sacrifice by determining tumor volume and calculated as
(length) (width2/2). All the animal studies were approved by the
local committee for animal care (IDIBELL, DAAM 5766).
High-grade ovarian serous PDX
Female nu/nu Swiss mice (strain NMRI-Foxn1nu/Foxn1nu) were
purchased from Janvier (Saint Berthevin, France). Mice were
housed and maintained in laminar flow cabinets under specific
pathogen-free conditions. All the animal studies were approved by
the local committee for animal care (IDIBELL, DAAM 5766).
The ovarian OVA200 and OVA265 used were perpetuated in 6-
week-old female nude mice by consecutive passages. Clinically
(FIGO classification), the primary tumor of both OVAs was classified
as stage III high-grade ovarian serous tumors. OVA265 presented a
deletion of the exon 20 c.(5243_5277+2788del; 5277+2916_5277+
2946delinsGG) in the BRCA1 gene. No BRCA1 or BRCA2 mutations
were detected in the OVA260 tumor.
When a palpable intra-abdominal mass was detected (3 months),
animals were randomized into two groups with similar tumor
volumes and metformin (100 mg/kg) was intraperitoneally adminis-
tered every day from Monday to Friday for 4 weeks. Control group
mice received intraperitoneal sterile serum under the same schedule
as metformin-treated mice. All mice also received a subcutaneous
injection of 500 ll of 5% glucose solution. The treatments had no
significant effect on mouse body weight, and the animals appeared
healthy and active throughout the study. Tumor response was eval-
uated at the moment of sacrifice by determining tumor volume and
calculated as (length) (width2/2).
Breast PDX
Breast BRCA1 patient-derived tumor xenografts (PDXs) have been
described elsewhere (Cruz et al, 2018).
Immunohistochemistry in paraffin-embedded samples
and scoring
Paraffin-embedded sections were deparaffinized in xylene and rehy-
drated in downgraded alcohols and distilled water. Antigens were
retrieved under high-pressure conditions for 4 min in citrate buffer,
pH 6. In the case of NDUFV2 detection, a pepsin digestion was also
performed. Endogen peroxidases were deactivated, and samples
were blocked with goat normal serum before primary antibody incu-
bation overnight at 4°C. 1/70 rabbit polyclonal anti-NDUFV2 anti-
body (Cat. NBP1-84475, Novus Biologicals, Littleton, CO) and 1/100
rabbit polyclonal anti-MCT4 (SLC16A3) (Cat. NBP1-81251, Novus
Biologicals, Littleton, CO) were used. Sections were incubated with
the specific secondary anti-rabbit EnVision antibodies (Dako,
Agilent Technologies, Santa Clara, CA), followed by the DAB devel-
oping system (Dako). Samples were counterstained with hema-
toxylin and visualized under light microscopy.
MCT4 and NDUFV2 were measured on the following grading
scale: no detectable signal (0 points); low-intensity signal (1 point);
moderate-intensity signal (2 points); and high-intensity signal (3
points). The labeling frequency was scored as the percentage of
positive tumor cells. The multiplicative index of intensity and label-
ing frequency was used in our analysis, as previously described
(Alsina-Sanchis et al, 2016).
Cell culture and media
The ID8 murine ovarian cancer cells used have been described
previously (Walton et al, 2016). We compared two genetically engi-
neered cell lines: ID8 Trp53-deleted and Trp53/Brca2-deleted ID8
cells. Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, 25 mM glucose, 1 mM pyruvate, Sigma-Aldrich) supple-
mented with 4% fetal bovine serum (GIBCO), L-glutamine, ITS
(5 lg/ml insulin, 5 lg/ml transferrin, and 5 ng/ml sodium selen-
ite), and antibiotics (100 U/ml penicillin and 0.1 mg/ml strepto-
mycin). In some experiments, we used DMEM complete medium
without pyruvate and supplemented or not with 1 mM pyruvate.
SKOV-3 (bought to Sigma-Aldrich in 2014, passages 5–20) ovarian
cancer human cells, murine ovarian cancer cells obtained from
tumors generated in mice with combinations of genetic alterations
(Trp53/, myc, and Akt or Trp53/, Brca1/, myc, and Akt)
(Xing & Orsulic, 2006) and murine Trp53-deficient or double Trp53/
Tsc2-deficient MEFs were cultured in DMEM (Sigma-Aldrich),
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supplemented with 10% fetal bovine serum (GIBCO), L-glutamine,
and antibiotics (100 U/ml penicillin and 0.1 mg/ml streptomycin).
All cells were grown at 37°C in a humidified atmosphere with 5%
CO2, and mycoplasma was tested by PCR every month.
To generate deletion of the BRCA2 gene in SKOV-3, we used
GenCRISPRTM gRNA/Cas9 lentiCRISPR v2 vector (GenScript, Piscat-
away, NJ) targeting the BRCA2 sequence CTGTCTACCTGAC
CAATCGA. SKOV-3 cells were infected with this vector or an empty
vector. After 2 days, cells were treated with puromycin (5 lg/ml)
and clones were isolated (SKOV-3-SC for the empty vector and
SKOV-3-BRCA2/ 1.2). Validation of the BRCA2 gene deletion was
performed by sequencing (STAB VIDA, Caparica, Portugal), increase
in the olaparib sensitivity (2.8 lM in SKOV-3-BRCA2/ 1.2
compared with 6.9 lM SKOV-3-SC), increase in the basal DNA
damage (staining for phospho-histone H2A.X Ser139), and loss of
the ability to form RAD51 foci after olaparib treatment compared
with the control cells (Appendix Fig S4 and (Walton et al, 2016)).
Cell viability assay
Cells were plated in 96-well plates, 750 cells per well, in eightpli-
cate. Cells were treated with the various compounds and respective
solvents for 3 days. Cell viability was determined as the final
number of cells detected on the cell culture plate, once they had
been fixed with methanol and crystal violet had been incorporated
(0.01%). Results were confirmed by measuring metabolic activity as
indicated by the methyl-thiazol-tetrazolium (MTT) assay (Sigma, St
Louis, MO). Briefly, when the treatment was finished, 10 lM MTT
was added to each well and incubated for an additional 4 h. The
blue MTT formazan precipitate was dissolved in DMSO, and the
optical density was measured (absorbance at 570 nm) on a multi-
well plate reader.
Mitochondrial respiration assay (Oxygraph)
Oxygen consumption was measured at 37°C in a high-resolution
oxygraph (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria).
Cells were seeded and grown to 60–70% confluence. They were
then detached with accutase and resuspended in medium at a final
concentration of 1 × 106 cells/ml. Basal oxygen consumption was
measured in the closed respirometer chamber and expressed as the
value per million viable cells. Oxygen flux, which is directly propor-
tional to oxygen consumption, was recorded continuously using
DatLab software 4.3 (Oroboros Instruments, Innsbruck, Austria).
Lactate production and glucose consumption assays
Cells were seeded in 12-well plate (3 × 105 cells per well) in quadru-
plicate. After 24 h, the medium was collected for analysis of L-
lactate and glucose. Cells were collected to check the protein content
for normalization. The concentration of L-lactate was determined
using an enzymatic reaction based on the oxidation of L-lactate to
pyruvate, as previously described (Alvarez et al, 2016). Lactate
production was calculated as the difference between lactate concen-
trations at 0 and 24 h. The concentration of glucose was determined
with the PGO (glucose oxidase/peroxidase) enzyme system (cat.
P7119, Sigma-Aldrich) and o-dianisidine as a colorimetric substrate.
The assay was performed in accordance with the manufacturer’s
instructions. Glucose consumption was calculated as the difference
between glucose concentration at 0 and 24 h.
Glycolytic rate measurement
The glycolytic rate was determined by measuring tritium release
from D-[5-3H] glucose to [3H] water in the reaction catalyzed by
enolase. Briefly, cells were seeded in 12-well plates (3 × 105 cells
per well) and, before measuring, incubated in basal medium with
1 lCi of D-[5-3H] glucose (American Radiolabeled Chemicals, St.
Louis, MO) per milliliter of medium for 60 min. After incubation,
50 ll aliquots of medium were transferred to uncapped microtubes
containing 50 ll of 0.2 N HCl. Each tube was placed in a scintilla-
tion vial containing 0.5 ml of cold H2O, avoiding contact between
the water in the vial and the contents of the microtube. The vials
were sealed to allow the [3H] water to evaporate from the microtube
and condense in the 0.5 ml of water at the bottom of the scintilla-
tion vial. Diffusion took place for 24 h at 37°C. The amount of dif-
fused and undiffused [3H] water was determined by scintillation
counting. A control sample containing no cells was used to correct
the [3H] water in the D-[5-3H]glucose. In addition, a sample contain-
ing a known quantity of [3H] water was used to determine the
completeness of diffusion. Protein content was used for normaliza-
tion.
NAD+ and NADH measurement
The concentrations of NAD+ and NADH were determined with the
NAD/NADH-GloTM Assay (cat. G9071, Promega, Madison, WI),
following the manufacturer’s instructions. Protein content was used
for normalization.
ATP levels
ATP concentration was determined using the StayBriteTM Highly
Stable Luciferase/Luciferin Reagent (cat. K790, BioVision, Milpitas,
CA), following the manufacturer’s instructions. Protein content was
used for normalization.
Metabolomics
ID8 Trp53-deleted and Trp53/Brca2-deleted cells were treated with
or without 5 mM metformin for 48 h in complete medium. The last
12-h medium was changed to basal DMEM, with or without
metformin and without pyruvate and glutamine, in the presence of
25 mM D-Glucose (U-13C6, Cat. CLM-1396-1, Cambridge Isotope
Laboratories Inc, Andover, MA). Afterward, cells were rinsed with
cold PBS, detached, centrifuged at 300 g for 5 min, and the pellet
frozen in liquid nitrogen.
Metabolites were extracted by adding 300 ll of cold methanol/
water (8:1, v:v). Samples were vortexed for 30 s and immersed in
liquid N2 to disrupt cell membranes followed by 10 s of bath sonica-
tion. These two steps were repeated three times. Cell lysates were
incubated for 20 min in ice before centrifugation (5,000 g, 15 min at
4°C). Ten microliter of 13C-glycerol (150 ppm) was added to the
supernatant as internal standard. Next, 250 ll of each sample was
dried under a stream of N2 gas. Lyophilized polar extracts were
incubated with 50 ll methoxyamine in pyridine (40 lg/ll) for
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45 min at 60°C. To increase volatility of the compounds, we sily-
lated the samples using 25 ll N-methyl-N-trimethylsilyltrifluoroace-
tamide with 1% trimethylchlorosilane (Thermo Fisher Scientific) for
30 min at 60°C. A 7890 A GC system coupled to a 7000 QqQ mass
spectrometer (Agilent Technologies, Palo Alto, CA.) was used for
isotopologue determination. Derivatized samples were injected
(1 ll) in the gas chromatograph system with a split inlet equipped
with a J&W Scientific DB5MS+DG stationary phase column
(30 mm × 0.25 mm i.d., 0.1- lm film, Agilent Technologies).
Helium was used as a carrier gas at a flow rate of 1 ml/min in
constant flow mode. The injector split ratio was adjusted to 1:5, and
oven temperature was programmed at 70°C for 1 min and increased
at 10°C/min to 325°C. The ionization performed was positive chemi-
cal ionization (CI) with isobutene as reagent gas. Mass spectral data
on the 7000 QqQ were acquired in scan mode monitoring selected
ion clusters of the different metabolites.
Mitochondrial mass detection assay (MitoTracker)
Cells were seeded in six-well plates at a density of 50,000 cells per
well. When cells reached the desired confluency (50–80%), culture
medium was removed, and pre-warmed (37°C) staining solution
containing the non-potential-dependent MitoTrackerTM Green FM
dye (1 lM) was added. Plates were incubated for 30 min at 37°C.
MitoTracker staining was analyzed by flow cytometry. Experiments
were carried out in triplicate for each set.
Mitochondrial (MitoSOX) superoxide production assay
Cells were seeded in six-well plates at a density of 50,000 cells per
well and grown to 50–80% confluence. MitoSOX Red solution was
added to a final concentration of 5 lM, in accordance with the
manufacturer’s recommendation. Cells were allowed to load
MitoSOX Red for 30 min and then washed three times with Hank’s
buffered salt solution (HBSS) containing calcium and magnesium.
For flow cytometry analysis, after 15 min of MitoSOX loading, all
three cell lines were trypsinized for 4 min and neutralized with
medium. Cells were centrifuged for 5 min at 300 g, resuspended
with HBSS containing 1% BSA/EDTA, and aliquoted into sterile
FACS tubes. MitoSOX Red was excited at 510 nm. Flow cytometry
was performed at different times. Experiments were carried out in
duplicate for each set.
Flow cytometry assay of phospho-histone H2A.X (Ser 139)
Cells were seeded in six-well plates at a density of 50,000 cells per
well and grown to 50–80% confluence. All cell lines were trypsi-
nized for 4 min and then washed three times with PBS. Cells were
centrifuged for 5 min at 600 g, resuspended in PFA 4%, and
aliquoted 100 ll into sterile FACS tubes. After 15-min incubation at
RT in the dark, cells were centrifuged and washed with PBS. Cells
were resuspended in 100 ll of Saponin buffer (3× Saponin buffer:
PBS, 1% BSA, 0.1% sodium azide, pH 7.4), and 5 ll of goat serum
was added during 15 min as a blocking step (final concentration of
5%). Cells were centrifuged and washed using 1–2 mL of 1×
Saponin buffer solution and centrifuged 2 min at 600 g. One
hundred microliter of 1× Saponin buffer solution was added with
1/100 rabbit polyclonal anti-phospho-histone H2A.X (Ser139)
antibody (Cat. ab11174, Abcam, Cambridge, UK) and incubated
30 min at RT in the dark. Cells were centrifuged and washed using
1–2 ml of 1× Saponin buffer solution, and resuspended in 100 ll of
1× Saponin buffer solution and the secondary Alexa Fluor 488 goat
anti-rabbit (Invitrogen, Thermo Fisher). After 30-min incubation at
RT in the dark, cells were centrifuged and washed using 1–2 ml of
1× Saponin buffer solution, resuspended in 100 ll of 1× Saponin
buffer solution, and staining was analyzed by flow cytometry.
Experiments were carried out in duplicate for each set.
Apoptosis analysis by flow cytometry
Cells (2 × 105) were seeded in 100-mm culture plates and, after
24 h, were treated with 5 lM olaparib or 5 mM metformin for
2 days. Afterward, cells were detached, centrifuged at 300 g for
5 min, and resuspended at a density of 5 × 105 cells/ml in 1× PBS-
1% FBS. Then, 100 ll of the cell suspension was mixed with
Annexin-V kit buffer (1:1; MuseTM Annexin-V & Dead Cell Assay,
Merck Millipore, Merck KGaA, Darmstadt, Germany). After 20 min
of incubation at room temperature, cells were examined in a MuseTM
Cell Analyzer (Merck Millipore). All conditions were assessed in
two independent experiments.
Cell cycle
After 2 days cell of culture with or without 2 mM metformin, cells
were detached, counted, and 1 million cells were centrifuged at
600 g for 5 min. The cell pellet was resuspended in 100 ll citrate
buffer (250 mM sucrose, 40 mM trisodium citrate dihydrate, pH
7.6) and treated with acotase. Samples were stained with propidium
iodide on ice for 10 min. Cells were analyzed in a FACSCalibur Flow
Cytometer running ModFit software.
Western blotting
Cells were lysed using RIPA lysis buffer and Western blot was
performed, as described elsewhere (Alsina-Sanchis et al, 2016). Blots
were incubated with 1/500 rabbit polyclonal anti-NDUFV2 antibody
(Cat. NBP1-84475, Novus Biologicals, Littleton, CO), 1/500 rabbit
polyclonal anti-MCT4 (SLC16A3) (Cat. NBP1-81251, Novus Biologi-
cals, Littleton, CO), 1/1,000 rabbit polyclonal anti-phospho-histone
H2A.X (Ser139) antibody (Cat. 2577, Cell Signaling Technologies), 1/
500 mouse monoclonal anti-VDAC1 antibody (Msa03, MitoSciences,
Abcam, Cambridge, UK), 1/1,000 rabbit polyclonal anti-GLUT-1 (Cat.
Ab652, Abcam, Cambridge, UK), 1/500 rabbit polyclonal anti-TIGAR
antibody (Cat. Santa Cruz, CA), 1/500 rabbit polyclonal anti-phospho-
PDH-E1a (Ser 293) antibody (Cat. AP1062, Calbiochem, Millipore), 1/
1,000 rabbit polyclonal anti-PDH-E1a antibody (Cat. AP1062, Calbio-
chem, Millipore), 1/1,000 rabbit polyclonal anti-phospho-ACC (Ser79)
antibody (Cat. 3661, Cell Signaling Technologies), 1/1,000 rabbit poly-
clonal anti-ACC antibody (Cat. 3676, Cell Signaling Technologies), 1/
1,000 rabbit polyclonal anti-PARP1 antibody (Cell Signaling Technolo-
gies), 1/1,000 monoclonal mouse anti-poly-ADP-ribose (PAR) anti-
body (Cat. AM80, Calbiochem, Millipore), 1/1,000 rabbit polyclonal
anti-histone H3 antibody (Cat. Ab1791, Abcam), 1/2,500 monoclonal
mouse anti-a-tubulin antibody (Sigma-Aldrich), or 1/2,500 mono-
clonal mouse anti-vinculin antibody (Sigma-Aldrich) in TBS contain-
ing 1% non-fat dry milk overnight at 4°C. Volumetric analysis was
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carried out using the Quantity One volume analysis tool (Bio-Rad,
Hercules, CA).
Nuclear extracts fractions
We adapted a protocol based on Murai et al (2012). Six millions of
cells were scrapped in cold PBS, centrifuged at 300 g for 5 min, and
resuspended in 150 ll hypotonic buffer (10 mM HEPES, pH 7.4,
1 mM EDTA, and 0.5 mM MgCl2) with protease inhibitors (0.1 lg/ml
benzamidine, 100 lM phenylmethylsulfonyl fluoride, 1 lM pepstatin
A, 1 lg/ml leupeptin, 4 lg/ml aprotinin). After 5 min at 4°C, 150 ll
hypotonic buffer containing 30% sucrose was added and then centri-
fuged at 12,000 g at 4°C 10 min. The pellet was resuspended in 150 ll
buffer A (50 mM HEPES, pH 7.4, 100 mM KCl, 2.5 mMMgCl2, 0.05%
Triton X-100 and protease inhibitors). This was H fraction (total
nuclear fraction). Seventy-five microliter of H was centrifuged at
12,000 g at 4°C 10 min. The supernatant was fraction 1. The pellet
was resuspended in 75 ll buffer B (50 mM HEPES, pH 7.4, 250 mM
KCl, 2.5 mM MgCl2, 0.05% Triton X-100 and protease inhibitors) and
centrifuged at 12,000 g at 4°C 10 min. The supernatant was fraction
2. The pellet was resuspended in 75 ll buffer C (50 mM HEPES, pH
7.4, 500 mM KCl, 2.5 mM MgCl2, 0.1% Triton X-100 and protease
inhibitors) and centrifuged at 12,000 g at 4°C 10 min. The super-
natant was fraction 3.
Quantitative real-time PCR
Total RNA from cells was extracted using TRIzol Reagent (Ambion,
Thermo Fisher Scientific). cDNA was obtained from a reverse tran-
scription reaction (High-Capacity cDNA Reverse Transcription Kit;
Applied Biosystems, Life Technologies, CA). Real-time PCR of cDNA
obtained was carried out on a LightCycler instrument (Roche Molec-
ular Biochemicals, Lewes, UK). After initial incubation at 95°C for
10 min, 40 cycles of amplification were performed with denatura-
tion at 95°C for 10 s, followed by annealing for 20 s (at 64°C) and
extension at 72°C for 13 s. The ΔCt values were calculated after
subtracting the mean Ct values of the b-actin gene from LdhB or
Hk2 mean Ct values. Results are presented as values of 2(ΔΔCt)
relative to ID8 Trp53-deleted cells values.
The mouse-specific primers used were LdhB (50-CATTGCGTCCG
TTGCAGATG and 50-GGAGGAACAAGCTCCCGTG), Hk2 (50-TGATC
GCCTGCTTATTCACGG and 50-AACCGCCTAGAAATCTCCAGA),
and the housekeeping gene b-actin (50-GGGGGTTGAGGTGTTGAG
and 50-GTCTCAAGTCAGTGTACAGGCC).
Gene expression analysis
Pre-processed and normalized data from breast and high-grade serous
ovarian tumors were taken from the NCI Genomic Data Commons data
portal. Somatic mutation data were obtained following approval by the
Data Access Committee (project #11689). The results published here
are partly based upon data generated by The Cancer Genome Atlas
(TCGA) (Cancer Genome Atlas Research Network, 2011), managed by
the National Cancer Institute (NCI, Bethesda) and National Human
Genome Research Institute (NHGRI, Bethesda). Information about
TCGA can be found at http://cancergenome.nih.gov. Mutational signa-
tures were defined using the R mutSignatures package. The gene set
enrichment tool, GSEA (Subramanian et al, 2005), was used with
default values selected for all parameters, and employing curated
KEGG gene sets, and the t-statistic of the gene expression differences
as a ranking metric. The expression signature scores were computed
using the ssGSEA algorithm with standard parameters and considering
all genes included in the OXPHOS gene set. ssGSEA gene expression
correlations were computed in R. Normalized gene expression data
from ovarian tumors treated with carboplatin in the CTCR-OV01 study
(GEO reference GSE15622) were analyzed using unpaired t-tests; these
assessments provided the statistic ranks used in subsequent GSEAs
with standard parameters.
The BRCA1/2 mutation status in primary breast and ovarian
tumors from TCGA studies was determined by annotations down-
loaded from the cBioPortal combined with curated information from
two publications (Kraya et al, 2019; Yost et al, 2019).
The non-TCGA ovarian cancer dataset included 152 patients
with high-grade serous ovarian cancer cared at the Cedars-Sinai
Medical Center, Ovarian Cancer Research Alliance, New York,
and compiled information included age at diagnosis, tumor stage,
progression-free survival, and overall survival. Total RNA from
formalin-fixed paraffin-embedded (FFPE) samples of omental
metastases from these 152 chemotherapy naı¨ve patients was
isolated using the miRNeasy FFPE kit according to the manufac-
turer’s instruction (Qiagen). RNA expression of genes included in
the PanCancer Progression Panel, Immunology Panel, and
custom-selected genes was analyzed by NanoString nCounter
technology. Data were normalized with nSolver software. To infer
the KEGG OXPHOS signature score in these tumors, we used as
surrogate genes whose expression is highly correlated with this
signature in RNAseq data from TCGA ovarian cancer. Ten genes
were selected that showed PCCs > 0.55 with KEGG OXPHOS in
TCGA data; then, these genes were used as a ssGSEA signature
to infer OXPHOS level in the independent ovarian cancer dataset.
Multivariate Cox regression analyses using the survfit and surv-
miner packages in R software were applied.
Pre-processed and normalized basal gene expression and IC50
responses in cancer cell lines were taken from the Genomics of Drug
Sensitivity in Cancer dataset (Iorio et al, 2016). The expression signa-
ture scores were computed using the ssGSEA algorithm calculated in
the GSVA package in Bioconductor (Hanzelmann et al, 2013).
Statistical analyses
Statistical analyses were carried out with SPSS for Windows 13.0
(SPSS, Inc., Chicago, IL) or GraphPad Prism 6.01 and in the R statisti-
cal environment. Differences between experimental and control
groups were determined using the Mann–Whitney U-test, Student’s t-
test, or the ordinary one-way ANOVA analysis. Animals in which
tumor implantation did not succeed (around 10–20% in every implan-
tation process) were excluded from the analysis and not included in
the final figure. Animals were grouped by similar tumor size after
palpation and assigned to control (animals treated with vehicle) or
metformin treatment randomly. No blinding was performed.
Data and software availability
Metabolomics: We include two Excel files as source data with the
metabolomic data we obtained (Figs 2F and 4A).
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The RNAseq datasets produced in this study are available at GEO
(Gene Expression Omnibus, NIH) under the accession number
GSE148310 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE148310).
Expanded View for this article is available online.
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